AKR7A3

Across TCGA pan-cancer cohorts, AKR7A3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AKR7A3 data layer compared with 19 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher AKR7A3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated AKR7A3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where AKR7A3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.650	0.322	<.001	73	view →
CCRCC	DFS	Quartile	III,IV	0.822	0.266	<.001	56	view →
LUAD	DFS	Median	All	0.515	0.758	.002	48	view →
HNSC	DFS	Tertile	III,IV	0.917	1.000	.032	11	view →
LSCC	OS	Tertile	II,III,IV	0.846	0.476	.017	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AKR7A3–PDAC (OS)

Open the PDAC breakdown →